# Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

> **NCT00095498** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 227 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** placebo
- **DRUG:** denosumab

## Key facts

- **NCT ID:** NCT00095498
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-11
- **Primary completion:** 2007-04-01
- **Final completion:** 2007-04-01
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095498, "Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00095498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*